As the U.S. stock market continues its upward momentum, driven by strong performances in large-cap technology stocks and positive economic indicators, investors are increasingly looking for promising growth companies with substantial insider ownership. High insider ownership often signals confidence from those closest to the company, making such stocks particularly appealing in a bullish market environment.
Top 10 Growth Companies With High Insider Ownership In The United States
Overview: Cipher Mining Inc., along with its subsidiaries, develops and operates industrial-scale bitcoin mining data centers in the United States and has a market cap of approximately $1.04 billion.
Operations: Cipher Mining Inc.'s revenue primarily comes from data processing, amounting to $158.67 million.
Insider Ownership: 17.2%
Revenue Growth Forecast: 47.5% p.a.
Cipher Mining, a growth company with substantial insider ownership, reported significant revenue growth to US$84.95 million for the first half of 2024 and became profitable with net income of US$24.61 million. Despite high volatility in its share price and recent insider selling, the company's earnings are forecasted to grow significantly at 60.9% annually, outpacing the market average. Recent activities include a $600 million equity offering and exploration of potential sale options amid takeover interest.
Overview: Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, and commercializing genetic medicines for rare diseases in the United States, with a market cap of $5.71 billion.
Operations: Krystal Biotech generates revenue by discovering, developing, and commercializing genetic medicines for patients with rare diseases in the United States.
Insider Ownership: 10.4%
Revenue Growth Forecast: 33% p.a.
Krystal Biotech, with substantial insider ownership, has shown impressive financial turnaround by reporting a net income of US$15.57 million for Q2 2024 compared to a net loss the previous year. The company’s revenue and earnings are forecasted to grow significantly at rates of 33% and 34.22% annually, respectively, outpacing the broader market. Despite recent shareholder dilution and high non-cash earnings, Krystal Biotech remains undervalued by approximately 53.7%.
Overview: Zeta Global Holdings Corp. operates an omnichannel data-driven cloud platform offering consumer intelligence and marketing automation software to enterprises globally, with a market cap of approximately $6.03 billion.
Operations: The company generates revenue primarily from its Internet Software & Services segment, which amounted to $822.09 million.
Insider Ownership: 14.9%
Revenue Growth Forecast: 17.3% p.a.
Zeta Global Holdings, with significant insider ownership, has raised its Q3 2024 revenue guidance to at least US$255 million, indicating strong growth. The company recently secured a US$550 million loan facility to refinance debt and enhance liquidity for potential acquisitions. Despite past shareholder dilution, Zeta's earnings are forecasted to grow substantially at 118.32% per year, and it aims to become profitable within three years while leveraging AI-driven data solutions for organic growth.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.